Mapping endpoints: building gene therapy trials for the future
How can gene therapy trials choose the best endpoints to navigate development and demonstrate patient value?

How can gene therapy trials choose the best endpoints to navigate development and demonstrate patient value?
The trial will include healthy subjects aged 18 to 55 years who will be randomised in 4:1 ratio, with 15 subjects per cohort.
The global pharmaceutical industry experienced a 10% rise in new job postings related to social responsibility in Q3 2022 compared…
Tevogen Bio reports positive data from Covid-19 T cell therapy trial
Cyrano to initiate Phase II trial of nasal spray therapy for Hyposmia
Shionogi commences Phase I/II/III and Phase III trials of Covid-19 vaccine
Ascletis doses subjects in first cohort of Covid-19 oral therapy trial